On this page
Study tools
Write your answer
Saved on this device. No marking — you are the marker.
Q1: NYHA vs ACC/AHA staging (2 min)
"What's the difference between NYHA class and ACC/AHA stage — aren't they both just severity scores?"
- NYHA class (I-IV) describes the patient's current functional symptoms and can improve with treatment — a patient started on GDMT can genuinely move from NYHA III to NYHA II.
- ACC/AHA stage (A-D) describes the objective disease trajectory — Stage A (at risk, no structural disease) through Stage D (advanced/refractory) — and a patient never moves backward through stages, even if their symptoms improve. A Stage C patient who becomes asymptomatic on treatment is still Stage C.
- Examiners test this distinction specifically because students conflate the two.[1]
Q2: The neurohormonal model (3 min)
"Explain why a failing heart activates systems that ultimately make it worse."
- A failing pump reduces cardiac output, which the body interprets as underperfusion and responds to with compensatory activation of the RAAS (renin → angiotensin II → vasoconstriction + aldosterone-driven sodium retention + hypertrophy/fibrosis) and the sympathetic nervous system (catecholamines maintaining output acutely but chronically causing cardiotoxicity, arrhythmia, and adverse remodelling).
- ADH/vasopressin also rises, causing water retention and the dilutional hyponatraemia of advanced disease.
- These systems are appropriate short-term compensations for acute blood loss or shock, but in chronic heart failure they become maladaptive, driving the remodelling that worsens the underlying disease — which is exactly why the four pillars of therapy each target one of these axes (ACE-inhibitor/ARNI → RAAS; beta-blocker → sympathetic; MRA → aldosterone directly).[1]
Q3: The four pillars — sequencing and evidence (3 min)
"Do you start all four pillars at once, or one at a time?"
- Modern practice favours starting all four together at low dose (sequenced by tolerability) rather than fully uptitrating one class before starting the next — each targets a different pathway, and delaying costs the patient mortality benefit.
- Know the trial behind each: CONSENSUS (enalapril), PARADIGM-HF (ARNI superior to enalapril), MERIT-HF (metoprolol/beta-blockade), RALES/EMPHASIS-HF (MRA), DAPA-HF/EMPEROR-Reduced (SGLT2 inhibitors).
- Practical caveat: a beta-blocker is only started once the patient is euvolaemic and haemodynamically stable — the guideline is explicit that persisting congestion, a systolic pressure under 90 mmHg, raised JVP, ascites or marked oedema should be relieved first, because the drug is a negative inotrope.[1]
Q4: HFpEF — why doesn't the HFrEF toolkit work? (2 min)
"A 78-year-old woman with hypertension and diabetes has heart failure symptoms but an LVEF of 60%. Do you give her the four pillars?"
- No — she has HFpEF, and the HFrEF pathophysiology (impaired contractility) doesn't apply here; her problem is a stiff, non-compliant ventricle with impaired relaxation and elevated filling pressures.
- Classic GDMT (ACE-inhibitor, beta-blocker, MRA at scale) has not shown consistent outcome benefit in HFpEF.
- The one exception: SGLT2 inhibitors (EMPEROR-Preserved, DELIVER) have shown benefit across the ejection-fraction spectrum — a class 1 recommendation in HFrEF and class 2a in HFmrEF and HFpEF.[2]
- Otherwise, management is diuretics for congestion plus aggressive control of the comorbidities that drive the syndrome — hypertension, diabetes, atrial fibrillation, and ischaemia.[1]
Q5: Acute pulmonary oedema (2 min)
"A patient with known HFrEF presents acutely breathless, SpO2 85%, BP 160/95. What do you do in the first ten minutes?"
- Sit upright, high-flow oxygen, IV furosemide 40-80 mg (the label gives 40 mg slow IV for acute pulmonary oedema, repeated at 80 mg if needed; in DOSE the high-dose strategy was more effective without clinically important renal effects), and IV nitrates (his BP permits this — nitrates are avoided if hypotensive).[3][1]
- Consider CPAP for ongoing respiratory distress — it reduces work of breathing and improves oxygenation via alveolar recruitment and preload/afterload reduction. In the meta-analysis the mortality reduction was seen with CPAP; bilevel ventilation reduced intubation but not mortality.[4]
- Look for and treat a precipitant — arrhythmia (especially new AF), ischaemia, infection, non-adherence, or excess salt/fluid intake — since untreated, the patient will simply decompensate again.
- If instead he were hypotensive with poor perfusion (cardiogenic shock), the approach would flip: inotropes and cause-directed therapy, not more diuretic.
Q6: Complications and prognosis (2 min)
"What determines whether this patient survives the next 12 months, and what would you do about sudden death risk?"
- Prognostic markers: LVEF, NYHA class, natriuretic peptide level, renal function, age, prior hospitalisation, and hyponatraemia (a marker of advanced, ADH-driven disease).
- A prior HF hospitalisation is itself one of the strongest predictors of further admissions and death — it is not just an isolated bad event.
- Sudden cardiac death from ventricular arrhythmia is a leading mode of death in HFrEF — for a patient with LVEF ≤35% despite optimal medical therapy, a primary-prevention ICD is indicated: in SCD-HeFT, NYHA II-III patients with an LVEF of 35 percent or less had a 23 percent lower risk of death with an ICD.[5][2]
References5ShowHide
- [1]McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Eur Heart J, 2021.PMID 34447992
- [2]Behnoush AH, Khalaji A, Naderi N, et al. ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison ESC Heart Fail, 2023.PMID 36460629
- [3]Campbell PT, Ryan J. Diuretic dosing in acute decompensated heart failure: lessons from DOSE Curr Heart Fail Rep, 2012.PMID 22699924
- [4]Winck JC, Azevedo LF, Costa-Pereira A, et al. Efficacy and safety of non-invasive ventilation in the treatment of acute cardiogenic pulmonary edema--a systematic review and meta-analysis Crit Care, 2006.PMID 16646987
- [5]Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med, 2005.PMID 15659722